Abstract: . . .  I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: cancer cancers rein Page 1 L E POINT SUR ... Progrès en Urologie (2001), 11, 368-375 368 Interleukine-6 et métastases osseuses du cancer du rein : bases moléculaires et implications thérapeutiques Bernard PAULE Service d’Urologie, Hôpital Henri Mondor, Créteil, France L’interleukine-6 (IL-6) est une cytokine [28] qui agit sur un grand nombre de cellules ; lymphocytes T et B, hépatocytes, cellules cardiaques, progéniteurs hémato- p o ï é t i q u e s … … L’IL-6 est un facteur de croissance autocrine [25] et/ou paracrine [29] des cellules myélo- mateuses. Dans le cancer du rein métastatique (CRm), un certain nombre d’arguments cliniques et expérimen- . . .
. . .  M., SCHLOSSMAN R.L., ANDERSON K.C. IL-6 trigger cell growth via the Ras-dependent mitogen-activated protein kinase cas- cade. J. Immunol., 1997, 159, 2212-2221. 45. PAULE B., CLERC D., RUDANT C., COULOMBEL C.. Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum. Pathol., 1998, 29 : 421-424. 46. PAULE B., CLERC D. Cancer du rein : métastases osseuses, immu- nothérapie et interleukine 6. Ann. Med. Int., 1999, 150, 4-9. 47. PAULE B., BELLOT J., RUDANT C., COULOMBEL C., ABBOU CC. Importance of IL-6 expression in primary human renal cell car- cinoma : an immunohistochemical study. J. Clin. Path., 2000, 53 : 388-390. 48. PAULE B., CLERC D., BRION N. Les bisphosphonates en cancéro- logie. Nouv. Presse Med., . . .
. . .  SCHLOSSMAN R.L., ANDERSON K.C. IL-6 trigger cell growth via the Ras-dependent mitogen-activated protein kinase cas- cade. J. Immunol., 1997, 159, 2212-2221. 45. PAULE B., CLERC D., RUDANT C., COULOMBEL C.. Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum. Pathol., 1998, 29 : 421-424. 46. PAULE B., CLERC D. Cancer du rein : métastases osseuses, immu- nothérapie et interleukine 6. Ann. Med. Int., 1999, 150, 4-9. 47. PAULE B., BELLOT J., RUDANT C., COULOMBEL C., ABBOU CC. Importance of IL-6 expression in primary human renal cell car- cinoma : an immunohistochemical study. J. Clin. Path., 2000, 53 : 388-390. 48. PAULE B., CLERC D., BRION N. Les bisphosphonates en cancéro- logie. Nouv. Presse Med., 2000, 29, . . .
. . .  multifunctional cytokine which provides multiple signals on various tissues and cells. In addition, IL-6 is produced by some human renal carcinoma cell lines in vitro and is expressed in a majority of primary renal cell carcinoma (RCC). Serum IL-6 influence the response to immunotherapy. IL- 6 appears as a target for rational drug design highly promising for development of new cancer therapies.IL-6 effects are media - ted by Stat. Stat (Signal transducers and activators of transcrip - tion) signaling pathways represent novel molecular targets for therapeutic implications in metastatic renal cell carcinoma. Inhibitors of Stat signaling pathway will not only block tumor growth by inducing apoptosis, but may also increase the sensi - tivity of tumors . . .
--3000,4,375,3314,39074